Related Experiment Video
Updated: Oct 29, 2025
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Updates and Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children
Suchitra K Hourigan1, Maribeth R Nicholson2, Stacy A Kahn3
1Pediatric Specialists of Virginia, Fairfax, VA.
Insights
Fecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection (rCDI) in children but faces regulatory and safety challenges. Biotherapeutics offer a promising alternative, though pediatric access may be delayed.
Area of Science:
- Microbiology
- Gastroenterology
- Pediatric Infectious Diseases
Background:
- Fecal microbiota transplantation (FMT) is the leading therapy for recurrent Clostridioides difficile infection (rCDI) in pediatric patients.
- Recent years have presented significant challenges to providing FMT, including an FDA safety alert in 2019 and disruptions from the COVID-19 pandemic.
- These challenges highlight the need for alternative and regulated treatments for pediatric rCDI.
Purpose of the Study:
- To discuss the current challenges and future directions of FMT in pediatric rCDI.
- To explore the potential of biotherapeutics as regulated alternatives to FMT for rCDI in children.
- To address concerns regarding limited access to effective rCDI treatments for pediatric patients.
Main Methods:
- This is a commentary discussing existing literature and regulatory landscapes.
- Analysis of safety alerts and pandemic-related impacts on FMT provision.
- Review of biotherapeutics as potential treatment options for rCDI.
Main Results:
- FMT, while effective, faces significant regulatory hurdles and safety concerns, exemplified by a 2019 FDA alert and pandemic-related issues.
- Biotherapeutics are emerging as promising, more regulated alternatives for rCDI treatment in adults.
- Regulatory approvals for biotherapeutics in children are anticipated to be substantially delayed, potentially limiting treatment access.
Conclusions:
- Pediatric patients with rCDI face evolving challenges in accessing effective FMT.
- Biotherapeutics represent a promising avenue, but delayed regulatory approval for pediatric use is a major concern.
- Future research and regulatory strategies are crucial to ensure continued access to effective rCDI therapies for children.
Abstract:
Fecal microbiota transplantation (FMT) is currently the most effective but loosely regulated therapy, for recurrent Clostridioides difficile infection (rCDI) in pediatrics. Over the last 2 years, there have been mounting challenges in the ability to provide FMT to pediatric patients. Firstly, an Food and Drug Administration (FDA) safety alert in 2019 reported transmission of a multidrug resistant organism from FMT donor to recipient resulting in the death of 1 patient. Secondly, the coronavirus disease 2019 (COVID-19) pandemic induced further safety and regulatory challenges. Biotherapeutics are promising and more readily regulated treatment options for rCDI, which may replace FMT in the near future for adults upon regulatory agency approvals. Such approvals, however, are expected to be significantly delayed for children, raising concerns for limited access to effective treatment for children with rCDI. In this commentary, we discuss the recent challenges and future directions of FMT and microbial therapeutics in children with rCDI.
